Improved tolerability profile of Locteron confirmed by data presented at EASL conference
(Thomson Reuters ONE) -
OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO) announces that its
licensee Biolex Therapeutics has presented yesterday, during the 45th
International Liver Congress (EASL) in Austria, a late-breaker poster containing
interim clinical results after 12 weeks of treatment with Locteron® from its
EMPOWER Phase IIb clinical study.
This study comprised 133 patients from two Phase IIb clinical studies. In line
with previous results, the interim data from EMPOWER confirm Locteron' superior
product profile, consisting of the following benefits:
* Reduced injection frequency: every other week as opposed to the current
standard of care which is administered every week
* Significant improvement in flu-like side effects: 50% reduction in flu-like
events or more
* Maintained anti-viral efficacy in reducing the hepatitis C viral load.
Simon Sturge, CEO of OctoPlus, says: "These additional data provide compelling
proof for Locteron's targeted benefits, which have been demonstrated
consistently in over 175 patients to date. We are very excited about these
results, which confirm our confidence in the potential of Locteron."
For detailed results we refer to Biolex' press release at www.biolex.com. The
poster will be available on the website of OctoPlus shortly. Later today Biolex
will give an oral presentation during the EASL conference.
For further information, please contact:
Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071, or
send an e-mail to Investor Relations at IR(at)octoplus.nl.
About Locteron
Locteron is a controlled release formulation of interferon alpha for the
treatment of chronic hepatitis C. Locteron combines OctoPlus' controlled release
drug delivery technology PolyActive® with Biolex' interferon alpha and is the
most advanced product in clinical development incorporating one of OctoPlus'
proprietary drug delivery technologies. OctoPlus licensed its commercial rights
to Locteron exclusively to Biolex in October 2008.
Locteron is an investigational therapeutic candidate and has not been approved
for sale by the United States Food and Drug Administration or by any
international regulatory agency.
About OctoPlus
OctoPlus is a drug delivery service company committed to the creation of
improved pharmaceutical products that are based on OctoPlus' proprietary drug
delivery technologies and have fewer side effects, improved patient convenience
and a better efficacy/safety balance than existing therapies. OctoPlus focuses
on the development of long-acting, controlled release versions of known protein
therapeutics, other drugs, and vaccines on behalf of its clients.
The clinically most advanced product incorporating our technology is Biolex
Therapeutics' lead product Locteron®, a controlled release formulation of
interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed
Locteron exclusively to Biolex in October 2008. Locteron is being manufactured
for Biolex by OctoPlus and is currently in Phase IIb clinical studies.
In addition, OctoPlus is a leading European provider of advanced drug
formulation and clinical scale manufacturing services to the pharmaceutical and
biotechnology industries, with a focus on difficult-to-formulate active
pharmaceutical ingredients.
OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO.
For more information about OctoPlus, please visit our website www.octoplus.nl.
This document may contain certain forward-looking statements relating to the
business, financial performance and results of OctoPlus and the industry in
which it operates. These statements are based on OctoPlus' current plans,
estimates and projections, as well as its expectations of external conditions
and events. In particular the words "expect", "anticipate", "predict",
"estimate", "project", "plan", "may", "should", "would", "will", "intend",
"believe" and similar expressions are intended to identify forward-looking
statements. We caution investors that a number of important factors, and the
inherent risks and uncertainties that such statements involve, could cause
actual results or outcomes to differ materially from those expressed in any
forward-looking statements. In the event of any inconsistency between an English
version and a Dutch version of this document, the English version will prevail
over the Dutch version.
[HUG#1404338]
Click here for the press release in PDF: http://hugin.info/137076/R/1404338/358458.pdf
Unternehmensinformation / Kurzprofil:
Datum: 16.04.2010 - 07:31 Uhr
Sprache: Deutsch
News-ID 19144
Anzahl Zeichen: 0
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 328 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Improved tolerability profile of Locteron confirmed by data presented at EASL conference"
steht unter der journalistisch-redaktionellen Verantwortung von
OctoPlus N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
